Peripheral Neuropathy Trial, Recruiting NCT06203093 Sponsor: New York Stem Cell Foundation Research Institute Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06203093
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 5 years or older.
  • People who have been diagnosed with Charcot-Marie-Tooth (CMT) disease, a hereditary nerve condition, or healthy people who can serve as a comparison group.
  • Adults must sign a written consent form, unless a physical limitation prevents them from signing.
  • Children having a skin sample taken for research must have a CMT diagnosis, and a parent or guardian must give consent on their behalf.
  • Children providing blood and/or saliva samples, or whose biological samples from a previous medical procedure are being used, may have a CMT diagnosis or be a healthy comparison participant, with a parent or guardian giving consent on their behalf.

Who may not be able to join:

  • People who are currently wards of the state (in government care).
  • For skin sample collection: people with a history of abnormal raised scarring (keloids), a blood clotting disorder, an allergy to local anaesthetic, or who are taking blood-thinning medications that would make the procedure unsafe.
  • For blood sample collection: people with a blood clotting disorder or other health conditions that would make blood collection more risky.
  • For any sample collection: people who are unwilling to follow the safety rules of the research organisation or partner sites.
  • For any sample collection: people with an AIDS diagnosis and a CD4 immune cell count below 200 cells per microlitre of blood, due to a higher risk of infection.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Laura Andres-Martin, New York Stem Cell Foundation Research Institute

Phone: 212-927-1801

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
New York Stem Cell Foundation Research Institute
Registry
ClinicalTrials.gov
Start date
22 September 2022
Est. completion
22 September 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Biobank

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov